Novo Nordisk is offering self-paying U.S. patients who are new to its weight-loss drug Wegovy their first month of medicine ...

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first ...

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, T2D and other metabolic diseases.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.